Jasinski Lawrence J 4

What Happened

• Lawrence J. Jasinski, a director of Lemaitre Vascular, reported five derivative award acquisitions on 2026-06-04. The filing shows accruals of dividend-equivalent rights totaling 4.071 shares (0.466, 0.558, 0.76, 0.86 and 1.427 shares) at a reported price of $0.00; total cash paid = $0.
• These are derivative awards (dividend equivalents) that vest proportionately with underlying restricted stock units (RSUs) or performance share units (PSUs). They are not open-market purchases or sales and do not reflect an immediate cash transaction.

Key Details

• Transaction date: 2026-06-04; Form 4 filed: 2026-06-05 (timely filing).
• Reported amounts and footnote mapping:
  • 0.466 DERs (accrued on RSU grant 12/8/2023) — F1
  • 0.558 DERs (accrued on PSU grant 12/8/2023) — F2
  • 0.760 DERs (accrued on RSU grant 12/6/2024) — F3
  • 0.860 DERs (accrued on PSU grant 12/6/2024) — F4
  • 1.427 DERs (accrued on RSU grant 12/10/2025) — F5
• Price reported: $0.00 per derivative right; total reported cash consideration: $0.
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• Filing timeliness: filed the day after the transaction (appears timely); no 10b5-1 plan or tax-withholding indication in the provided notes.

Context

• Dividend-equivalent rights simply track cash dividends that accrue on unvested RSUs/PSUs and will be paid or converted in accordance with the underlying award terms when those awards vest. They are derivative accruals, not stock purchases or option exercises, and do not by themselves indicate a buy/sell sentiment.